BiomX Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $21.3M | $24.7M | $16.7M | $16.2M | $22.7M |
| Operating expenses | — | — | — | $376,000 | — |
| Operating income | -$41.5M | -$44.5M | -$25.3M | -$27.2M | -$35.5M |
| Interest expense | $20,000 | $873,000 | $2.4M | $2.1M | $699,000 |
| Pretax income | -$36.2M | -$17.7M | -$26.1M | -$28.3M | -$36.2M |
| Income tax expense | $7,000 | $13,000 | $23,000 | $65,000 | $67,000 |
| Net income | -$36.2M | -$17.7M | -$26.2M | -$28.3M | -$36.2M |
| Balance Sheet | |||||
| Cash and equivalents | $4.4M | $16.9M | $14.9M | $31.3M | $62.1M |
| Current assets | $5.6M | $20.5M | $17.6M | $36.9M | $66.6M |
| Total assets | $5.8M | $43.2M | $25.0M | $45.5M | $78.0M |
| Current liabilities | $6.4M | $8.3M | $11.2M | $7.9M | $11.0M |
| Total debt | — | — | $10.7M | $14.9M | — |
| Stockholders' equity | -$1.3M | $24.1M | $3.1M | $21.0M | $47.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$26.4M | -$37.0M | -$21.3M | -$29.1M | -$27.6M |
| Depreciation and amortization | $2.9M | $1.8M | $871,000 | $909,000 | $1.8M |
| Stock-based compensation | $2.1M | $1.8M | $1.1M | $1.5M | $3.2M |
| Capital expenditure | $2,000 | $30,000 | $50,000 | $112,000 | $3.7M |
| Free cash flow | -$26.4M | -$37.0M | -$21.3M | -$29.2M | -$31.3M |
| Impairments | $11.8M | $3.2M | — | — | — |
Shares outstanding 10.1M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.